Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th Post published:October 5, 2023 Post category:Press Release
Clearmind Medicine Closes US$2.25 Million Public Offering Post published:September 18, 2023 Post category:Press Release
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering Post published:September 14, 2023 Post category:Press Release
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder Post published:September 6, 2023 Post category:Press Release
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company Post published:August 14, 2023 Post category:Press Release
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio Post published:August 1, 2023 Post category:Press Release
Clearmind Medicine Announces Share-Based Payment for the Company’s Consultants Post published:July 18, 2023 Post category:Press Release
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine’s Scientific Advisory Board Post published:July 11, 2023 Post category:Press Release
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome Post published:June 16, 2023 Post category:Press Release
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder Post published:May 22, 2023 Post category:Press Release